Amoy Diagnostics Co., Ltd.

Shenzhen Stock Exchange 300685.SZ

Amoy Diagnostics Co., Ltd. Operating Income Margin for the year ending December 31, 2023: 28.87%

Amoy Diagnostics Co., Ltd. Operating Income Margin is 28.87% for the year ending December 31, 2023, a -15.48% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Amoy Diagnostics Co., Ltd. Operating Income Margin for the year ending December 31, 2022 was 34.16%, a 23.69% change year over year.
Amoy Diagnostics Co., Ltd. Operating Income Margin for the year ending December 31, 2021 was 27.61%, a -0.50% change year over year.
Amoy Diagnostics Co., Ltd. Operating Income Margin for the year ending December 31, 2020 was 27.75%, a -1.20% change year over year.
Amoy Diagnostics Co., Ltd. Operating Income Margin for the year ending December 31, 2019 was 28.09%, a -14.32% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Shenzhen Stock Exchange: 300685.SZ

Amoy Diagnostics Co., Ltd.

CEO	Ms. Ying Chen
IPO Date	Aug. 3, 2017
Location	China
Headquarters	39 Dingshan Road
Employees	1,119
Sector	Healthcare
Industries Biotechnology

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

Key trends

Past 5 years